Saturday 17 October 2026 Export DBVT’s income statement to Excel — free account

DBV Technologies S.A.

DBV Technologies S.A.’s revenue for fiscal 2025 (year ended December 2025) was $5.6 million, up 35.8% from fiscal 2024. In the quarter to June 2026, revenue fell 53.3%, EPS grew 61.3% and free cash flow fell 56.2%, each against the same quarter a year earlier.

9.05 0.06 −0.66%

Follow DBVT

Alert me

Market cap: $572.6M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: 4/9
Altman Z: 1.33
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 15.51

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	1	1	—	—	—	—	—	1	—	—	—

Insider Ownership 37.50%

Capital & Financial Ratios $m

Market Cap 572.56

Revenue 4.94

Net Income (175.95)

Free Cash Flow (170.61)

Net Debt (174.90)

Current Ratio 3.72

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E —

P/S ratio 158.97

P/B ratio 4.89

Past 5Y EPS Growth —

This Y EPS Growth 28.64%

Next Y EPS Growth 43.06%

Next Y revenue growth —

Next 5Y EPS Growth 56.91%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 90.65%

10-year low 10-year high

P/B against its own 10 years 83.45%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	141	32	194	175
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	18	12	19	27
	159	44	213	202

	2023	2024	2025	Q'26
Payables	23	22	41	39
ST’ Debt	—	—	—	—
Other	13	8	16	14
	37	31	58	54

Compound Annual Growth %

	10y	5y	3y
Sales	(1.93%)	(12.95%)	5.18%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(7.23%)	(3.86%)	(4.61%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	1	1	—	—	—
’25	1	2	3	1	6
’24	1	1	1	1	4
’23	2	2	2	9	16
’22	3	2	2	(1)	5
’21	3	(1)	1	3	6
’20	5	4	4	(1)	11

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(49)	(53)	—	—	—
’25	(20)	(34)	(32)	(35)	(121)
’24	(35)	(35)	(22)	(12)	(104)
’23	(21)	(26)	(20)	(14)	(80)
’22	(1)	(10)	(20)	(24)	(56)
’21	(36)	(30)	(23)	(19)	(108)
’20	(50)	(38)	(45)	(34)	(166)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(49)	(53)	—	—	—
’25	(20)	(34)	(33)	(36)	(122)
’24	(36)	(36)	(23)	(12)	(107)
’23	(21)	(26)	(20)	(14)	(80)
’22	(2)	(10)	(20)	(24)	(56)
’21	(36)	(30)	(23)	(19)	(109)
’20	(51)	(38)	(45)	(34)	(168)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.56)	(0.60)	—	—	—
’25	(1.32)	(1.55)	(1.20)	(1.15)	(5.25)
’24	(1.40)	(1.70)	(1.58)	(1.10)	(5.85)
’23	(1.10)	(1.30)	(0.90)	(0.60)	(3.80)
’22	(1.50)	(1.80)	(0.90)	(2.30)	(6.20)
’21	(2.70)	(2.80)	(2.20)	(1.30)	(8.90)
’20	(3.95)	(1.81)	(2.82)	(3.59)	(14.80)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	45.10	41.16	7.20	11.54	2.70	2.70	2.16	1.30	0.44	3.15	Analyst estimates 2026–2028 Powerpack
	High	75.96	101.14	53.96	22.46	26.98	14.76	6.86	4.74	4.50	26.19
People
People	Employees	164	244	315	311	142	92	85	104	109	125
	Revenue/emp, $m	0.06	0.06	0.05	0.05	0.08	0.06	0.06	0.15	0.04	0.05
Income, $m
Income, $m	Revenue	10	13	17	15	11	6	5	16	4	6
	Gross margin, %	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(127)	(167)	(196)	(171)	(160)	(98)	(96)	(73)	(114)	(146)
	EBT margin, %	(1,260.79)	(1,240.18)	(1,142.33)	(1,165.36)	(1,415.09)	(1,720.20)	(1,986.04)	(462.35)	(2,743.03)	(2,598.58)
	Net income	(127)	(167)	(196)	(172)	(160)	(98)	(96)	—	(114)	(147)
	Depreciation	1	3	3	3	10	8	13	(14)	(1)	3
Per share, $
Per share, $	Revenue	2.06	2.72	2.97	1.99	1.04	0.52	0.31	0.83	0.21	0.20
	Earnings	(25.90)	(33.70)	(33.90)	(23.30)	(14.80)	(8.90)	(6.20)	(3.80)	(5.85)	(5.25)
	Cash flow	(13.47)	(26.10)	(27.89)	(20.04)	(15.31)	(9.86)	(3.60)	(4.19)	(5.39)	(4.34)
	Capex	(1.86)	(1.72)	(0.97)	(0.76)	(0.26)	(0.03)	(0.05)	(0.04)	(0.12)	(0.02)
	Free cash flow	(15.33)	(27.82)	(28.86)	(20.80)	(15.56)	(9.88)	(3.64)	(4.22)	(5.51)	(4.36)
	Book value	54.95	29.66	24.76	26.10	18.99	9.04	12.56	7.37	1.41	6.05
	Shares, m	5	5	6	7	11	11	15	19	19	28
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	0.00	0.00	5.03	6.16	9.59	2.29	14.44	94.95
	P/B	0.00	0.00	0.00	0.00	0.28	0.35	0.24	0.26	2.19	3.17
	EV/Sales	0.00	0.00	0.00	0.00	(12.34)	(7.35)	(33.56)	(6.69)	6.66	60.52
	EV/FCF	0.00	0.49	0.32	0.39	0.83	0.39	2.88	1.31	(0.26)	(2.80)
Cash, $m
Cash, $m	Operating cash flow	(66)	(129)	(161)	(148)	(166)	(108)	(56)	(80)	(104)	(121)
	Capex	(9)	(9)	(6)	(6)	(3)	0	(1)	(1)	(2)	(1)
	Free cash flow	(75)	(138)	(167)	(154)	(168)	(109)	(56)	(80)	(107)	(122)
Balance, $m
Balance, $m	Working capital	269	137	120	151	155	83	194	122	13	155
	Total debt	4	2	2	1	1	7	1	—	—	—
	Net debt	(279)	(154)	(143)	(192)	(196)	(77)	(209)	(141)	(32)	(194)
	Shareholders’ equity	269	147	143	193	205	99	194	140	27	169
Returns, %
Returns, %	ROA	(36.25)	(64.32)	(97.14)	(72.49)	(58.66)	(46.69)	(48.96)	(33.87)	(91.63)	(98.17)
	ROIC	0.00	0.00	0.00	(14,425.02)	(1,025.38)	(280.50)	0.00	0.00	0.00	0.00
	ROE	(40.47)	(80.34)	(135.22)	(102.26)	(80.04)	(64.19)	(65.55)	(43.47)	(135.96)	(149.83)

Negative figures in brackets.

value withheld pending a data check

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
OLMA Olema Pharmaceuticals, Inc.	$601.1M	— (loss-making)	—	—	n/m	−54.33% (below 0%: shrinking)	0.00%	0.00%	Compare
CRMD CorMedix Inc	$581.5M	3.0×	16.5×	+156.52% (above 0%: growing)	+13.79% (above 0%: growing)	+185.90% (above 0%: growing)	75.66%	42.10%	Compare
SLN Silence Therapeutics PLC Sponsored ADR	$581.1M	— (loss-making)	— (loss-making)	+197.18% (above 0%: growing)	n/m	+106.95% (above 0%: growing)	97.39%	0.00%	Compare
SGMT Sagimet Biosciences Inc.	$574.7M	— (loss-making)	— (loss-making)	—	n/m	−21.95% (below 0%: shrinking)	100.00%	0.00%	Compare
DBVT DBV Technologies S.A.	$572.6M	— (loss-making)	—	−53.33% (below 0%: shrinking)	n/m	−56.15% (below 0%: shrinking)	100.00%	(7,228.57%)
VALN Valneva SE Sponsored ADR	$560.4M	59.7×	19.4×	−17.29% (below 0%: shrinking)	n/m	−56.05% (below 0%: shrinking)	15.29%	(76.67%)	Compare
STTK Shattuck Labs, Inc.	$555.0M	— (loss-making)	— (loss-making)	−10.31% (below 0%: shrinking)	n/m	+1.01% (above 0%: growing)	100.00%	0.00%	Compare
VECT VectivBio Holding AG	$545.5M	— (loss-making)	— (loss-making)	—	n/m	—	91.93%	0.00%	Compare
PBYI Puma Biotechnology, Inc.	$543.0M	18.2×	24.2×	+7.75% (above 0%: growing)	+33.33% (above 0%: growing)	−88.45% (below 0%: shrinking)	77.92%	13.42%	Compare
Median of peers	$567.5M	18.2×	19.4×	+7.75%	—	−21.95%	84.93%	0.00%

All 614 Biotechnology stocks →

DBV Technologies S.A. (DBVT) key facts

Strength: DBV Technologies S.A.’s revenue for fiscal 2025 (year ended December 2025) was $5.6 million, up 35.8% from fiscal 2024.
DBV Technologies S.A. (DBVT) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, DBVT traded at $9.05, a market capitalization of $572.6 million.
Return on equity was −149.8% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is 1.33 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.